Secondary hyperparathyroidism
MONDO:0006964Overproduction of parathyroid hormone in response to influence external to the parathyroid glands.
Also known as: secondary hyperparathyroidism, secondary hyperparathyroidism (disease), secondary hyperparathyroidism NOS
34 clinical trials for this condition and its sub-types, 19 tagged with Secondary hyperparathyroidism itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Secondary hyperparathyroidism
-
Secondary hyperparathyroidism of renal origin 7 trials · 18 incl. sub-types
1 sub-type
- Renal osteodystrophy 12 trials
-
New injection shows promise for dialysis patients with hormone imbalance
Disease control CompletedThis study tested a new drug called MT1013 in 115 adults with chronic kidney disease who are on dialysis and have a condition called secondary hyperparathyroidism (high parathyroid hormone). The goal was to see if the drug could safely lower hormone levels by at least 30%. Partic…
Phase 2 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New injection aims to tame hormone chaos in kidney dialysis patients
Disease control CompletedThis study tests a new drug called SHR6508 in 303 adults on hemodialysis who have secondary hyperparathyroidism, a condition where parathyroid hormone levels get too high. The drug is given as an injection to help control these hormone levels and related minerals like calcium and…
Phase 2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug shows promise for dialysis patients with hormone disorder
Disease control CompletedThis study tested a new drug called MT1013 in 98 adults on kidney dialysis who have secondary hyperparathyroidism, a condition where parathyroid hormone levels are too high. The goal was to see if the drug is safe and can lower these hormone levels. Participants received either t…
Phase 2 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New drug SHR6508 aims to tame hormone imbalance in dialysis patients
Disease control CompletedThis study tested a new drug called SHR6508 in 498 adults on hemodialysis who have secondary hyperparathyroidism, a condition where the parathyroid glands make too much hormone. The drug is given during dialysis and was compared to an existing oral medication, cinacalcet. The goa…
Phase 3 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug aims to tame parathyroid glands in dialysis patients
Disease control CompletedThis study tested a drug called PLS240 in 412 adults with end-stage kidney disease on dialysis who also have overactive parathyroid glands (secondary hyperparathyroidism). Participants received either PLS240 or a placebo intravenously three times a week for 27 weeks, followed by …
Phase 3 • Sponsor: Pathalys Pharma • Aim: Disease control
Last updated Jun 26, 2026 14:53 UTC
-
New drug aims to tame parathyroid glands in dialysis patients
Disease control CompletedThis study tested a drug called PLS240 in 362 adults with end-stage kidney disease on dialysis who also have overactive parathyroid glands (secondary hyperparathyroidism). Participants received either PLS240 or a placebo during dialysis three times a week for 27 weeks, followed b…
Phase 3 • Sponsor: Pathalys Pharma • Aim: Disease control
Last updated Jun 26, 2026 14:38 UTC
-
Dialysis Patients' heart risk: a new prediction model under study
Knowledge-focused CompletedThis study follows adults receiving maintenance hemodialysis for end-stage kidney disease to develop a model that predicts the risk of dying from cardiovascular disease. Researchers will track routine lab results, including how often blood phosphate levels stay in a target range,…
Sponsor: Huashan Hospital • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC
-
Tiny trial tracks new Drug's journey in dialysis patients
Knowledge-focused CompletedThis early-stage study looks at how the experimental drug MT1013 moves through and leaves the body of people on hemodialysis who have secondary hyperparathyroidism. Six participants will receive a single dose, and researchers will measure radioactivity in blood, urine, and stool …
Phase 1 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Tiny study tracks kidney Drug's exit route in dialysis patients
Knowledge-focused CompletedThis completed Phase 1 study looked at how a radioactive form of the drug SHR6508 is processed and eliminated in 5 Chinese adults on hemodialysis who have secondary hyperparathyroidism. The main goal was to measure how much radioactivity ends up in urine and stool, and to identif…
Phase 1 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC